ClinConnect ClinConnect Logo
Search / Trial NCT06882317

Long Term Follow-up Study for Subjects Administered CLBR001

Launched by CALIBR, A DIVISION OF SCRIPPS RESEARCH · Mar 12, 2025

Trial Information

Current as of May 09, 2025

Not yet recruiting

Keywords

Long Term Follow Up (Ltfu) Clbr001 Autologous Cell Therapy Switchable Car T Cell Cell And Gene Therapy

ClinConnect Summary

This clinical trial is a long-term follow-up study designed to keep track of patients who have received a treatment called CLBR001. CLBR001 is a type of gene therapy that uses special technology to help the body fight certain conditions. The main goal of this study is to monitor participants for up to 15 years after they received the treatment to see if there are any delayed side effects or problems that may come up later on.

To participate in this study, individuals must be between the ages of 65 and 74 and have received at least one dose of the CLBR001 treatment. There are no specific exclusions for this trial, which means most people who qualify can join. Participants can expect to be monitored over the years for their health and any effects related to the treatment. This study is important because it helps researchers understand the long-term safety and effectiveness of gene therapies like CLBR001.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects who received at least one CLBR001 cell dose.
  • Exclusion Criteria:
  • None

About Calibr, A Division Of Scripps Research

Calibr, a division of Scripps Research, is a pioneering biotechnology organization dedicated to advancing the discovery and development of transformative therapies. Leveraging cutting-edge science and innovative technologies, Calibr focuses on translating high-impact research into clinically viable solutions for unmet medical needs. The organization collaborates with academic institutions, industry partners, and clinical investigators to accelerate the progress of novel treatments, particularly in the fields of immunology, oncology, and regenerative medicine. With a commitment to excellence and a patient-centered approach, Calibr aims to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Patients applied

0 patients applied

Trial Officials

Chief Medical Officer

Study Director

Calibr-Skaggs Institute for Innovative Medicines

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported